KRAS and Patent ductus arteriosus: Remarkably, GSK3α mainly regulates the NF-κB response in Kras mutations harboring Panc-1 and MiaPaCa-2 PDA cells, where the GSK3 inhibitor AR-A014418 decreases its proliferation.